FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
AstraZeneca-Backed Breast Cancer Treatment Under European Regulatory Review for Type II Variation
EU Health Agency Validates Daiichi Sankyo, AstraZeneca's Application for Breast Cancer Drug
Express News | Daiichi Sankyo And AstraZeneca's ENHERTU Receives Breakthrough Therapy Designation In The U.S. For Specific Patients With HER2 Low Or Ultralow Metastatic Breast Cancer
J&J, Roche Come Out on Top in S&P Ratings of Strongest Pharma Companies
Trending Stocks This Week as U.S. Equities Notch Their Best Week of 2024
Ryand83 OP : $罗氏(ADR) (RHHBY.US)$ $阿斯利康 (AZN.US)$
Ryand83 OP : 本来是说 400
不是 500。关键是罗氏要把我们搞得一团糟